Lumora Attracts Second Stage Funding
News May 25, 2011
Lumora Ltd, the Molecular diagnostics company, developing next generation tests through its proprietary BART Technology platform, has secured £1.5 million from the completion of the company’s latest funding round, led by Catapult Venture Managers Ltd.
The capital injection will primarily be used to accelerate Cambridgeshire-based Lumora’s entry into the clinical molecular diagnostic market, which is already valued at $6 billion and has the potential for explosive growth in emerging markets.
The company’s development programmes focus on applications which benefit from the robust, affordable, easy-to-use nature of their core technology, such as an integrated testing station for gastrointestinal (GI) infections and an HIV viral load monitoring system to support drug therapy in the developing world.
Catapult has invested just over £1 million from its Catapult Growth Fund, with the balance coming from a follow-on investment from Lumora’s major shareholder, Tate & Lyle Ventures LP.
Having proven the technology within food safety testing, the company now plans to enter the much larger clinical diagnostics sector.
Lumora has developed the simplest ever platform for molecular diagnostics based on an innovative signalling chemistry. The technology allows tests to be performed at a single temperature and without the need for expensive optics, hence hardware is uniquely simple and low-cost.
Laurence Tisi commented: “The platform is uniquely low-cost for both hardware and consumables and so represents an exciting new approach to bringing the advantages of molecular diagnostics to resource limited settings. Lumora is already collaborating with an internationally renowned not-for-profit organisation in the field of HIV viral load monitoring.”
Ed Wass, Catapult Investment Director, commented: “We are delighted to have the opportunity to work with Lumora’s excellent management team, led by CEO Laurence Tisi. We have also introduced a Non-Executive director to the Board - Jim Reid - who has a strong track record in the molecular diagnostic sector and who has worked previously for several major companies in the space, including Roche and Chiron, as well as being a successful entrepreneur in his own right.”
“An exciting application for Lumora’s technology is provision of a low cost solution for HIV testing in less developed regions, such as Africa, where there is generally less access to the current higher cost, more sophisticated laboratory alternatives.”
David Atkinson, Managing Partner of Tate & Lyle Ventures LP commented: ”We are delighted to welcome Catapult Venture Managers as an investor in Lumora along side Tate & Lyle Ventures. Having successfully developed the technology for use in the food sector, Lumora has identified a number of exciting opportunities in the larger clinical market and now has the financial resources to help it deliver in these areas. “
“The technology has already been proven for food safety testing, and Lumora is now exploring commercial partnerships for clinical diagnostics.”
Ed Wass concluded: “Lumora is a very exciting company with great prospects and vision and we are very pleased to be supporting its future growth.”
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer’s disease – even before they show signs of confusion and memory loss, according to a new study from Washington University School of Medicine in St. Louis and the German Center for Neurodegenerative Diseases in Germany.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019